Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Investment Securities: 2012-2025

Historic Gains from Investment Securities for Enanta Pharmaceuticals (ENTA) over the last 12 years, with Jun 2025 value amounting to $98,000.

  • Enanta Pharmaceuticals' Gains from Investment Securities fell 72.63% to $98,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $2.2 million, marking a year-over-year decrease of 90.53%. This contributed to the annual value of $5.8 million for FY2025, which is 11.09% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $98,000 for Q2 2025, which was down 82.31% from $554,000 recorded in Q1 2025.
  • Enanta Pharmaceuticals' 5-year Gains from Investment Securities high stood at $22.4 million for Q1 2024, and its period low was $83,000 during Q3 2023.
  • For the 3-year period, Enanta Pharmaceuticals' Gains from Investment Securities averaged around $3.1 million, with its median value being $547,000 (2024).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Gains from Investment Securities surged by 1,275.00% in 2022 and then tumbled by 97.53% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $4.2 million in 2021, then slumped by 80.25% to $825,000 in 2022, then tumbled by 77.82% to $183,000 in 2023, then spiked by 198.91% to $547,000 in 2024, then crashed by 72.63% to $98,000 in 2025.
  • Its last three reported values are $98,000 in Q2 2025, $554,000 for Q1 2025, and $547,000 during Q4 2024.